Dana V. Rizk

A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy

Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial

Proteinuria Trajectory and Disease Progression in Children and Adults with IgA Nephropathy/Vasculitis

Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial

What do clinical trials teach us about the pathophysiology of human IgA nephropathy?

Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy

An Update on Current Therapeutic Options in IgA Nephropathy

Targeting APRIL in the treatment of glomerular diseases

Primary IgA Nephropathy: New Insights and Emerging Therapies

WCN24-1837 BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY

State-of-Art Therapeutics in IgA Nephropathy

Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study

Targeting the Endothelin A Receptor in IgA Nephropathy

Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy

Targeting APRIL in the Treatment of IgA Nephropathy

Colocalization of IgG and IgA Heavy Chains with Kappa and Lambda Light Chains in Glomerular Deposits of IgA Nephropathy Patients Using High-Resolution Confocal Microscopy and Correlation with Oxford MEST-C Scores

CureGN-Diabetes Study: Rationale, Design, and Methods of a Prospective Observational Study of Glomerular Disease Patients with Diabetes

New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies

POS-546 EFFICACY AND SAFETY OF IPTACOPAN IN IgA NEPHROPATHY: RESULTS OF A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY AT 6 MONTHS

Cytokines and Production of Aberrantly <i>O</i> -Glycosylated IgA1, the Main Autoantigen in IgA Nephropathy

Lactated Ringer's solution and risk of hyperkalemia in patients with reduced kidney function

Phosphatase control of cytokine-mediated overproduction of galactose-deficient IgA1, the main autoantigen in IgA nephropathy

IgA vasculitis with nephritis: update of pathogenesis with clinical implications

An Update on the Current State of Management and Clinical Trials for IgA Nephropathy

IgA Nephropathy: An Interesting Autoimmune Kidney Disease

Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy

The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy

Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1

Confidence in Women’s Health: A Cross Border Survey of Adult Nephrologists